IMPACT OF LIVING WITH EPILEPSY

Patients have a lot to lose with just 1 seizure

WHEN SEIZURES REMAIN UNCONTROLLED, PATIENTS ARE1*:

Uncontrolled Seizure Patient with Depression Icon

6X

more likely
to have
depression

Red Car Driving Icon

4.5X

more likely
to be prevented
from driving

Briefcase Icon

3X

more likely to
experience limitations
in employment

Graduation Cap and Diploma Icon

2X

more likely
to have limits in
education

Patients with seizures have an increased risk of SUDEP2†

Higher rates of SUDEP (up to 9.3 deaths per 1,000 person-years) have been reported in patients with drug-resistant epilepsy.3,4

*Based on data that compared patients who had ≥1 seizure in the past 5 years with those who experienced no seizures in the past 5 years.
†Based on data that compared patients who had ≥1 seizure in the previous year with those who had zero seizures.
 SUDEP=sudden unexpected death in epilepsy.

HEAR FROM SELIM R. BENBADIS, MD, ON THE NEED FOR THE SUDEP CONVERSATION

The risk of complacency:
Talking to patients about SUDEP

In this video, hear Dr Benbadis speak to the importance of fighting complacency in drug‑resistant patients, and why discussing the risk of SUDEP with patients who continue to face uncontrolled seizures can be a critical conversation to have.

Browse our expert videos and patient stories to hear more.

References: 1. Josephson CB, Patten SB, Bulloch A, et al. The impact of seizures on epilepsy outcomes: a national, community-based survey. Epilepsia. 2017;58(5):764-771. 2. Nilsson L, Farahmand BY, Persson P-G, Thiblin I, Tomson T. Risk factors for sudden unexpected death in epilepsy: a case-control study. Lancet. 1999;353(9156):888-893. 3. Devinsky O, Hesdorffer DC, Thurman DJ, Lhatoo S, Richerson G. Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention. Lancet Neurol. 2016;15(10):1075-1088. 4. Casadei CH, Carson KW, Mendiratta A, et al. All-cause mortality and SUDEP in a surgical epilepsy population. Epilepsy Behav. 2020;108:107093.

HISTORY OF ANTI-SEIZURE MEDICATIONS (ASMs)

Many patients have a history of being let down

During the past 3 decades, despite new ASMs coming to market, seizure freedom rates have remained nearly the same1,2*

RATES OF ZERO SEIZURES BY DECADE OF APPROVAL FOR A RANGE OF ASMs3†

1990-19994,5

2.1%-8.7%

vs 0%-2.2% with placebo

2000-20096,7

2.2%-7.4%

vs 0.8%-1.2% with placebo

2010-20198-10

2.0%-8.2%

vs 0%-2% with placebo

Prior to the 1990s, there was little information on seizure freedom rates with ASMs used as add-on therapy—and even less information about how these rates were determined3

*Seizure freedom was defined as a patient experiencing no seizures for the previous 12 months or longer.1
†Data from pivotal trials.

EPILEPSY IS NOT AS CONTROLLED AS YOU MAY THINK

XCOPRI Icon

HEAR FROM SELIM R. BENBADIS, MD, ON THE DANGERS OF UNCONTROLLED EPILEPSY

Why seizure freedom must remain the goal

In this video, Dr Benbadis discusses the importance of trying different treatment options in patients with epilepsy who remain drug‑resistant—his goal is always to aim for seizure freedom.

Browse our expert videos and patient stories to hear more.

Explore a treatment option that can provide the possibility of zero seizures

See the Efficacy

Expand your epilepsy knowledge

Learn More at XCOPRI University
References: 1. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279-286. 2. Chen Z, Brodie MJ, Liew D, Kwan P. Unchanged treatment outcomes in patients with newly diagnosed epilepsy treatment with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2017. doi:10.1001/jamaneurol.2017.3949 3. Halford JJ, Edwards JC. Seizure freedom as an outcome in epilepsy treatment clinical trials. Acta Neurol Scand. 2020;142(2):91-107. 4. Keppra [package insert]. Smyrna, GA: UCB, Inc; 2020. 5. Topamax [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2009. 6. Vimpat [package insert]. Smyrna, GA: UCB, Inc; 2021. 7. Sabril [package insert]. Deerfield, IL: Lundbeck; 2009. 8. Fycompa [package insert]. Woodcliff Lake, NJ: Eisai Inc; 2021. 9. Aptiom [package insert]. Marlborough, MA: Sunovion Pharmaceuticals, Inc; 2019. 10. Potiga [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2011.
Expand

INDICATION

XCOPRI® (cenobamate tablets) CV is indicated for the treatment of partial‑onset seizures in adult patients.

Important Safety Information
and indication

CONTRAINDICATIONS
XCOPRI® is contraindicated in any patients with known hypersensitivity to the compound or any of the components of the drug product.
XCOPRI is contraindicated in patients with Familial Short QT syndrome.

Close IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION and INDICATION for XCOPRI® (cenobamate tablets) CV

CONTRAINDICATIONS

XCOPRI is contraindicated in any patients with known hypersensitivity to the compound or any of the components of the drug product.

XCOPRI is contraindicated in patients with Familial Short QT syndrome.

WARNINGS AND PRECAUTIONS

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Also known as Multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including XCOPRI. DRESS has been reported, including one fatality, when XCOPRI is titrated rapidly (weekly or faster titration). No cases of DRESS were reported in an open-label safety study of 1339 partial-onset seizure patients when XCOPRI was initiated at 12.5 mg/day and titrated every two weeks. This finding does not establish that the risk of DRESS is prevented by a slower titration; however, XCOPRI should be initiated at 12.5 mg once daily and titrated every two weeks. DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement. Eosinophilia is often present. If such signs or symptoms are present, the patient should be evaluated immediately. XCOPRI should be discontinued immediately and not restarted if an alternative etiology for the signs or symptoms cannot be established.

QT Shortening: XCOPRI can cause shortening of the QT interval. Caution should be used when administering XCOPRI and other drugs that shorten the QT interval as there may be a synergistic effect on the QT interval that would increase the QT shortening risk.

Suicidal Behavior and Ideation: Antiepileptic drugs (AEDs), including XCOPRI, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Advise patients, their caregivers, and/or families to be alert for these behavioral changes and report them immediately to a healthcare provider.

Neurological Adverse Reactions: XCOPRI causes dose-dependent increases in the neurologic adverse reactions including, dizziness, diplopia, disturbance in gait and coordination, somnolence, and fatigue.

Prescribers should advise patients against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous machinery, until the effect of XCOPRI is known.

Withdrawal of AEDs: As with all antiepileptic drugs, XCOPRI should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus. But if withdrawal is needed because of a serious adverse event, rapid discontinuation can be considered.

MOST COMMON ADVERSE REACTIONS

In adult adjunctive therapy placebo-controlled clinical studies, the most common adverse reactions that occurred in XCOPRI-treated patients (incidence at least 10% and greater than placebo) were somnolence, dizziness, fatigue, diplopia, headache.

DOSING CONSIDERATIONS

Dosage adjustment of XCOPRI or other concomitant medications may be necessary.

  • Consider gradually reducing phenytoin dosages by up to 50% during initial titration.
  • Consider reducing dosages of phenobarbital and clobazam as needed when used concomitantly with XCOPRI. When XCOPRI and carbamazepine or lamotrigine are taken concomitantly, consider increasing dosages as needed of carbamazepine or lamotrigine.
  • Consider increasing dosages as needed of drugs which are CYP2B6 and CYP3A substrates and decreasing dosages as needed of drugs which are CYP2C19 substrates.
  • Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control.

Dosage reduction of XCOPRI may be considered in patients with mild to moderate and severe renal impairment. XCOPRI use is not recommended in end‑stage renal disease.

The maximum recommended daily dose is 200 mg for patients with mild or moderate hepatic impairment. XCOPRI use is not recommended in patients with severe hepatic impairment

DRUG ABUSE

XCOPRI is a Schedule V controlled substance.

INDICATION

XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.

Please see full Prescribing Information.